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Hepatocellular carcinoma (HCC) is the most common
primary malignancy of the liver, with extrahepatic metastasis
typically found during disease progression [1,2].
Edmondson and Steiner reported from autopsy findings
that the adrenal gland is the second most common site for
metastasis, secondary to the lung [3]. Clinically, however,
HCC metastasis to the adrenal gland is rare. When adrenal
metastasis is observed, it requires aggressive management,
due to the risk of rupture and internal hemorrhage.
Experience in the management of adrenal metastasis from
HCC is limited [4,5], and current practice calls for
adrenalectomy as the main treatment option, followed by
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transcatheter arterial chemoembolization (TACE, Allura
Monoplane Angiography System; Philips, Amsterdam,
Netherlands) therapy [4,6]. Radiation therapy, with or
without the combination of TACE or percutaneous ethanol
injection (PEI) therapy, is rarely used [7]. This case report
details our experience in the management of bilateral
adrenal metastasis from HCC, using radiation therapy and
TACE. Such experience may prove useful in the disease
management of such patients.
CASE PRESENTATION
In March 1995, a 57-year-old male with liver cirrhosis
secondary to hepatitis C was diagnosed with a single nodule
of HCC. The nodule, which measured 20 mm in diameter,
was not surgically resected, given his persistently elevated
alanine transferase (ALT) titer (150–200 IU/L).  This level
© 2005 Elsevier. All rights reserved.
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was considered to reflect active chronic hepatitis (ALT level
> 100 IU/L), and the patient was thus considered at risk of
progression to severe hepatitis or even hepatic failure,
following general anesthesia. Under these circumstances,
operative intervention was considered inappropriate and
TACE was first performed on August 1, 1995. Following the
procedure, the patient received interferon therapy (Welforn
3Mu/tiw) for 24 weeks, as treatment for chronic hepatitis C.
The nodule became a hypoechoic lesion with an acoustic
shadow and no dominant daughter nodule or mosaic pattern
in this hopoechic lesion, after PEI therapy was performed in
September 1995.
Unfortunately, during the follow-up period, multiple
new HCC nodules were detected and our clinical judgment
was that neither PEI nor TACE would be suitable for treating
these recurrent nodules. During this period, the patient was
asymptomatic. A very large left adrenal tumor measuring
73 mm in diameter was detected during regular follow-up by
ultrasound, in October 2002. Comparative abdominal
computed tomography (CT) showed not only a very large
left adrenal tumor, but also a small right adrenal tumor
(Figure 1A). At this time, the masses were still clinically
silent, with no detectable symptom or sign (such as
hypertension), Cushing syndrome or electrolyte imbalance,
which might relate to the abnormal function of the adrenal
gland. There was also no abdominal or back pain. TACE for
the left adrenal tumor was performed via the left adrenal
artery, with Lipiodol 1 mL, and mitomycin 1 mL, followed by
the embolizing agent, gelfoam pledget. The effect was very
unsatisfactory, given the difficult catheterization of the arteries
supplying the tumor (Figure 1B). Through this procedure,
the left adrenal tumor was also targeted with 3D-conformal
radiation therapy (200 cGy/day, total 5,400 cGy, November
to December 2002, by Varian Linear Accelerator 2100CD).
Follow-up angiography performed 1 month after
radiation therapy showed marked devascularization of the
left adrenal tumor, but a few supplying arteries still
remained. Therefore, 3D-conformal radiation was
performed again (200 cGy/day, total 4,800 cGy, February to
March 2003). After the therapy, there were no detectable
gastrointestinal symptoms suggestive of radiation field
damage. The size of the left adrenal tumor was reduced to
less than 30 mm (Figure 2A) and the follow-up angiography
performed in  October  2003  showed complete
devasculization of the tumor (Figure 2B). No recurrence of
left adrenal metastasis has yet to be found.
The right adrenal tumor was also treated by TACE (8 mL
Lipiodol ultra-fluid mixed with 50 mg cisplatin, 40 mg
epirubicin and 6 mg mitomycin C, followed by embolization
with gelfoam pledget, via right adrenal artery). Follow-up
CT performed 1 month after TACE showed complete filling
of Lipiodol ultra-fluid within the right adrenal tumor.
However, the right adrenal tumor did not reduce
significantly in size and progressively enlarged soon after
Figure 1. (A) Contrast-enhanced computed tomography shows a very large left adrenal tumor (white arrow) and a small right adrenal tumor
(black arrows). (B) Angiography shows a hypervascular left adrenal tumor (white arrows) with multiple supplying arteries originating from the
left renal arteries (black arrow).
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TACE (Figure 2A). The second cycle of TACE for the right
adrenal tumor was performed in October 2003 (10 mL
Lipiodol ultra-fluid mixed with 30 mg epirubicin and 6 mg
mitomycin C, followed by embolization with gelfoam
particles). A post-embolized abdominal echo revealed
incomplete filling of the Lipiodol ultra-fluid within the
tumor, and the patient was then additionally offered 3D
conformal radiation therapy to the right adrenal tumor
(200 cGy/day, total 5,400 cGy, December 2003 to January
2004) (Figure 3).
No detectable complication for radiation therapy was
found. The right adrenal tumor was estimated by
ultrasound at 1 month after radiation therapy to have
reduced in size by 10 mm, the patient has yet to present
evidence of pulmonary or bony metastasis, and the
intrahepatic HCC tumors were well controlled by PEI and
TACE. The patient’s condition remains stable, and the
liver function has been maintained at a Child A status
(early stage for liver cirrhosis) [8]. The serum alpha-
fetoprotein, blood urea nitrogen, and serum creatinine
levels have since been maintained within normal ranges,
post diagnosis of HCC and for the entire follow-up period.
DISCUSSION
The incidence of adrenal metastasis from HCC at autopsy
ranges from 5% to 11% [3]. The route for metastasis is
considered hematogenous, but there is also a possibility of
direct invasion [9].  Adrenal metastasis is often
asymptomatic, unless progressive enlargement of the tumor
Figure 2. (A) Contrast-enhanced computed tomography shows the size of the left adrenal tumor (white arrows) decreased significantly to less than
30 mm. The size of the right adrenal tumor (black arrows) increased significantly. The Lipiodol was compressed to the center of the tumor by the cancer
cells that had recurred. (B) Angiography shows complete devascularization of the left adrenal tumor (the black arrow indicates the left renal artery).
Figure 3A. Isodose of radiotherapy for the right adrenal tumor, showing
the dosage distribution of the energy of 3D-conformal radiotherapy.
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is such that compressive symptoms are generated [10]. This
metastasis is usually detected by imaging studies during
regular follow-up of patients.
In this case report, surgery could not be offered because
of the presence of active chronic hepatitis C. The left adrenal
tumor was first detected by ultrasound when it was 73 mm
in size, and the right adrenal tumor was undetectable by
ultrasound. The patient had been regularly followed by
ultrasound at intervals of 2–3 months. The sudden appearance
of a very large left adrenal tumor may have been due to a
rapid growth of the tumor. At the time, the patient did not
complain of any specific symptoms. Ultrasound, it should be
noted, is a limited scanning method when surveying the
adrenal gland. This limitation comes from the gland’s location
and the frequent interference by intestinal gas.
Moreover, a biopsy of the adrenal mass was not
performed because of a difficult approach due to interference
from an enlarged spleen and small bowel, hypervascularity
of the adrenal mass, and the patient’s unwillingness. CT
scans are more sensitive than ultrasound in the examination
of adrenal gland, because CT is not interfered with by bowel
gas and is more sensitive to deep lesions, particularly in the
retroperitoneal organs.
Adrenalectomy may cure adrenal metastasis of HCC,
but this treatment method carries the risks inherent in such
operations. Moreover, Momoi and Shimahara have reported
no significant difference in survival between patients treated
by adrenalectomy and those by TACE or PEI [4]. In their
report, however, the sample number was small and requires
validation. In this case, adrenalectomy was not performed,
as metastases were present bilaterally, and the patient’s
previous cardiovascular history augmented the significant
morbidity and mortality risks associated with the procedure.
TACE may be effective in the palliative management of
adrenal metastasis [4,6]. Essentially, the success of TACE
therapy relies on the ability to approach and embolize the
whole of the artery supplying the tumor. This is the reason
why the left adrenal tumor in the present case report could
not be satisfactorily treated by TACE. Another determinant
factor for successful TACE therapy is the cancer cells’
sensitivity to the anticancer drugs. The intrahepatic HCC
tumors in the present case could be successfully controlled
by TACE with the same anticancer drugs for adrenal
metastasis. Therefore, recurrence of right adrenal tumor
after TACE was considered a result from failure to detect
some of the very small supplying arteries on angiography for
embolization. For this patient, given the difficulty with
catheterization, the effectiveness of TACE was not maximal.
Radiation therapy for adrenal metastasis, for its part,
carries the risk of damaging the adjacent organs. For the
treated patient in our report, the total radiation dose for the left
adrenal tumor was extremely high. Nevertheless, there were
no detectable complications, because we used 3D conformal
radiation with multi-left collimator to protect adjacent organs
Figure 3B. Dose volume histograms of the
3D-conformal radiotherapy for the right
adrenal tumor.
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such as the liver, kidney, and spinal cord. In addition, the
location of the left adrenal tumor was precisely located by
ultrasound before 3D conformal radiation therapy, and the
dose was divided into 65% from posterior projection and 35%
from anterior projection. In this instance, this procedure may
have helped reduce unwanted damage to the gastrointestinal
system, kidney and spinal cord. Moreover, the application
of 3D-conformal radiation therapy may have further reduced
the possibility of damage to the adjacent organs.
The right adrenal tumor was not initially treated with
radiation therapy, as the large left adrenal tumor was the
main priority. Three-dimensional conformal radiation
therapy was, however, eventually applied to the right
adrenal tumor as well, due to the rapid recurrence of tumor
after TACE. The initial result from the radiation therapy
was satisfactory. There was no significant influence of
radiation on liver and renal function, as the target was
precisely located by ultrasound before radiation. It should
be noted, however, that the patient is still being monitored,
as the symptoms associated with radiotherapy may only
appear after a year or longer. Following the interventions
detailed above, no aberrant renal or liver functions
manifested, and no special symptoms, such as those
suggestive of hyperaldosteronism or hypoaldosteronism
(Cushing’s or Addison’s syndrome), were found.
In conclusion, this case report details a satisfactory
effect of radiation therapy for the treatment of adrenal
metastasis from HCC. The complication of radiation can be
minimized by precise location of the target.
REFERENCES
1. Maki A, Takayatsu T, Mori K, et al. Studies on multidisciplinary
therapy for recurrent hepatocellular carcinoma after hepatic
resection. Jpn J Gastroenterol Surg 1989;22:779–82.
2. Castroagudin JF, Gonzalez-Quintela A, Martinez J, et al. Bilateral
adrenal metastasis from hepatocellular carcinoma after liver
transplantation. Hepatogastroenterology 2002;49:249–51.
3. Edmondson HA, Steiner PE. Primary carcinoma of the liver –
a study of 100 cases among 48,900 necropsies. Cancer 1954;7:
462–503.
4. Momoi H, Shimahara Y. Management of adrenal metastasis
from hepatocellular carcinoma. Surg Today 2002;32:1035–41.
5. Inagaki Y, Unoura M, Urabe T, et al. Distant metastasis of
hepatocellular carcinoma after successful treatment of the
primary lesion. Hepatogastroenterology 1993;40:316–9.
6. Taniai N, Egami K, Wada M, et al. Adrenal metastasis from
hepatocellular carcinoma (HCC): report of 3 cases.
Hepatogastroenterology 1999;46:2523–8.
7. Takada K, Nakamura K, Usuki N, et al. Adrenal arterial
embolization and radiotherapy of a case with metastatic adrenal
tumor and its tumor thrombus in inferior vena cava from
hepatocellular carcinoma. Jpn J Clin Radiol 1989;34:1529–32.
8. Green GB, Harris IS, Lin GA, et al. Table 17–5. In: The Washington
Manual of Medical Therapeutics. Philadelphia: Lippincott
Williams & Wilkins, 2004:397.
9. Okuda K, Arakawa M, Kubo Y, et al. Right-sided pedunculated
hepatocellular carcinoma: a form of adrenal metastasis.
Hepatology 1998;27:81–5.
10. Kuromatsu R, Hirai K, Majima Y, et al. A patient with
hepatocellular carcinoma who underwent resection of the
primary lesion 10 years ago and resection of a giant adrenal
metastasis 8 and a half years later. Gastroenterol Jpn 1993;28:
312–6.
M.H. Hsieh, Z.Y. Lin, C.J. Huang, et al
Kaohsiung J Med Sci August 2005 • Vol 21 • No 8376
 !"VP==R==Q=
 !"VQ==P==U=
 !"#$%&'
 !"!#$%&'( )*+,-.
 !"#$%&'NMM
 !"#$%&'()*+ !
 
N
= = 
N
= = 
O
= = 
P
= = 
N
 !"!#$%&'( )= =
N
 !"= =
O
 !"= =
P
 !
 !"#"$%&'()*+,-./0123456 1"#%&78
 !"#$%&'()*+,-./0")*123(4+56789")*:
 !"#$%&'()*+,-./01234567%8#9:;<=>9?
 !"#$%&'()*+,-./01234567(8 !"#$%&
 !"#PaJÅçåÑçêã~ä !" !#$%&'"()*+,-./012
 !"#$%&'()*+,-./0123456789:;*<89=>
 !"#$%&'()#*+,-PaJÅçåÑçêã~ä !ERIQMMÅdóF 
 !"#$%&N !"#$%&'()=`ÜáäÇ=^= !"#$%&'
 !"#$%&'()*+,-./01234567$890:;-<=>?
 !"#$%&'
 ! !"#$%"&'(")*+,"-./012345+,
 !"=OMMRXONWPTNJS
